193 related articles for article (PubMed ID: 31841561)
1. Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes.
Xu H; Perez RD; Frey TR; Burton EM; Mannemuddhu S; Haley JD; McIntosh MT; Bhaduri-McIntosh S
PLoS Pathog; 2019 Dec; 15(12):e1008228. PubMed ID: 31841561
[TBL] [Abstract][Full Text] [Related]
2. STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.
McIntosh MT; Koganti S; Boatwright JL; Li X; Spadaro SV; Brantly AC; Ayers JB; Perez RD; Burton EM; Burgula S; MacCarthy T; Bhaduri-McIntosh S
PLoS Pathog; 2020 Oct; 16(10):e1008849. PubMed ID: 33002095
[TBL] [Abstract][Full Text] [Related]
3. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
4. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of Epstein-Barr virus-associated diseases.
Kutok JL; Wang F
Annu Rev Pathol; 2006; 1():375-404. PubMed ID: 18039120
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
7. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes.
Klein G; Klein E; Kashuba E
Biochem Biophys Res Commun; 2010 May; 396(1):67-73. PubMed ID: 20494113
[TBL] [Abstract][Full Text] [Related]
8. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Noguchi K
Yakugaku Zasshi; 2019; 139(1):63-67. PubMed ID: 30606931
[TBL] [Abstract][Full Text] [Related]
9. Current Trends and Alternative Scenarios in EBV Research.
Minarovits J; Niller HH
Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
[TBL] [Abstract][Full Text] [Related]
10. Proof for EBV's sustaining role in Burkitt's lymphomas.
Vereide D; Sugden B
Semin Cancer Biol; 2009 Dec; 19(6):389-93. PubMed ID: 19628040
[TBL] [Abstract][Full Text] [Related]
11. The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.
Dyson OF; Pagano JS; Whitehurst CB
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724765
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
14. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.
Cohen JI
Semin Hematol; 2003 Apr; 40(2):116-23. PubMed ID: 12704588
[TBL] [Abstract][Full Text] [Related]
15. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
16. Burkitt Lymphomas Evolve to Escape Dependencies on Epstein-Barr Virus.
Hutcheson RL; Chakravorty A; Sugden B
Front Cell Infect Microbiol; 2020; 10():606412. PubMed ID: 33505922
[TBL] [Abstract][Full Text] [Related]
17. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
18. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.
Chen X; Kamranvar SA; Masucci MG
Oncogene; 2016 Jul; 35(29):3807-16. PubMed ID: 26592445
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.
Stuhlmann-Laeisz C; Szczepanowski M; Borchert A; Brüggemann M; Klapper W
Virchows Arch; 2015 Jan; 466(1):85-92. PubMed ID: 25339301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
